Latest Commercialisation News

1414 Degrees has completed all technical milestones with Woodside, retaining full ownership of its SiBox technology and advancing commercialisation efforts in industrial decarbonisation and hydrogen.

Artrya Limited has raised A$75 million through a two-tranche placement and launched a A$5 million share purchase plan to fast-track the U.S. commercialisation of its AI-powered Salix platform following FDA clearance.

Proteomics International Laboratories announces the planned retirement of its founder and Managing Director, Dr Richard Lipscombe, in February 2026, marking a pivotal leadership transition as the company seeks a new CEO to drive its next growth phase.

Livium Ltd has inked a term sheet with the University of Melbourne to exclusively commercialise innovative microwave technology for rare earth elements extraction, promising high recovery rates and major energy savings.

NuEnergy Gas Limited has obtained government approval to sell 1 MMSCFD of coal bed methane gas in Indonesia, marking a pivotal step in its transition to production and supporting the country’s energy security goals.

Alterity Therapeutics has raised A$20 million through a strategic placement to advance its promising ATH434 treatment for Multiple System Atrophy, backed by encouraging Phase 2 trial results. The capital injection strengthens the company’s balance sheet as it prepares for regulatory discussions with the FDA.

Imagion Biosystems has reached key milestones in its MagSense® HER2 breast cancer imaging program, including starting manufacturing for its Phase 2 trial and launching an AI imaging protocol collaboration with Wayne State University.

Coda Minerals has announced a fully underwritten $8.33 million entitlement offer to fund the pre-feasibility study of its Elizabeth Creek Copper-Silver Project, offering shareholders a discounted entry price with attaching options.

D3 Energy has submitted its Production Right application for part of its South African ER315 permit well ahead of schedule and under budget, marking a key step toward commercialising certified methane and helium reserves.

Memphasys has inked a five-year exclusive distribution agreement with Middle East leader ITL, unlocking a $325,000 initial order for its Felix™ fertility system upon CE Mark approval. This deal opens access to 15 countries and over 350 IVF clinics, setting the stage for rapid regional adoption.

Cambium Bio has secured a strategic partnership with French pharmaceutical leader Benta SAS to commercialise its regenerative dry eye treatment, Elate Ocular, across Europe and the Middle East. This follows a second platelet-lysate licensing deal within days, underscoring growing industry confidence in Cambium’s platform.

Carnegie Clean Energy has secured a pivotal role in a €4 million European Commission-funded project aimed at advancing wave energy technology and reducing costs. The initiative leverages Carnegie’s CETO platform to pioneer innovations that could reshape the future of ocean energy farms.